INS and Hyperglycemia: This suggests that the CGM data may have helped identify nocturnal hypoglycemia or other glycemic metrics suggestive of excessive basal insulin dosing [15], where patients may benefit from reducing their basal insulin dose and possibly from adding bolus insulin doses or other antihyperglycemic therapies to address unrecognized postprandial hyperglycemia.